PRFX (painreform.com) Market Value to Book Value Ratio

Official company branding of PainReform Ltd (PRFX)

The prospects of PainReform Ltd. (PRFX) depend on regulatory approvals and the efficacy of extended-release pain management systems. This P/BV chart visualizes asset value dynamics, where 0.14 represents the current value of the metric. Business growth relies on the integration of the PRF-110 platform into surgical protocols and a strategy of organic expansion within the hospital sales network without external acquisitions.

PRFX PainReform Corp: Market Value to Book Value in the range 07/04/2022 - 10/27/2026
Original product of PainReform Limited

This indicator compares the current market value of the business with its net assets to confirm the strength of the fundamental trend. By analyzing the chart of the market cap to book value multiple, an investor assesses the smoothness of the market's revaluation of the company. The metric measures the gap between book value and market expectations, revealing hidden vulnerability to debt. For PainReform Ltd. (PRFX), this gap reflects the speculative value of future FDA approvals. The competence of the Israeli management in R&D and the transparency of the pipeline make such market premiums justified.

Main competitors

Market Cap to Net Assets Ratio Haleon plc|KVUE (kenvue.com) - Capitalization to Book Value Ratio|Market Value to Book Value Ratio Verona Pharma VRNA|Market Capitalization to Net Assets Jyong Biotech Limited|Ligand Pharma (LGND) - Market Capitalization to Book Value Ratio|Market Value to Book Value Amneal Corp (AMRX)|Market Capitalization to Book Value Ratio PRGO (Perrigo Company plc)|alvotech.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Liquidia (LQDA)|GLPG: Market Value to Book Value|ANIP (ANI Pharma) - Market Value to Book Value Ratio|Afrezza (MNKD) - Market Cap to Net Assets Ratio|AMPH (Amphastar Pharmaceuticals) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio pacira.com (PCRX)|ARS Pharmaceuticals, Inc. (SPRY) - Market Cap to Net Assets Ratio|Market Value to Book Value TBPH (Theravance Biopharma Inc)|AQST: Market Value to Book Value Ratio|SCPH - Market-to-Book Ratio|Market Cap to Net Assets Ratio Tectonic TECX|TNXP - Market Cap to Book Value Multiple|Market Capitalization to Book Value Ratio sxtchina.com SXTC|Eupraxia Pharmaceuticals Inc. (EPRX) - Market Value to Book Value|Market Capitalization to Book Value Ratio BHST (BioHarvest)|Market-to-Book Ratio EXOZ|Oramed Pharmaceuticals (ORMP) - Market Value to Book Value Ratio|Market Value to Book Value ENTX (enterabio.com)|MindWalk Holdings Inc. (HYFT) - Market Value to Book Value Ratio|Market Capitalization to Net Assets ABVC BioPharma Inc. ABVC|Cumberland Pharma - Market Capitalization to Book Value Ratio|QNTM - Market Capitalization to Book Value Ratio|FibroGen, Inc. - Market Capitalization to Book Value Ratio|TELO (telomirpharma.com) - Market Capitalization to Book Value|Market Value to Book Value Ratio Rani Therapeutics Holdings (RANI)|Capitalization to Book Value Ratio SNYR|Rallybio Corporation (RLYB) - Market Value to Book Value Ratio|Market Value to Book Value lexariabioscience.com (LEXX)|PULM: Market Capitalization to Book Value Ratio|Market-to-Book Ratio Pheton Holdings Limited PTHL|Market Capitalization to Book Value Ratio Aptorum|LYRA: Market Capitalization to Net Assets|Market Value to Book Value Ratio IBO|TNFA (TNF Pharmaceuticals, Inc.) - Market-to-Book Ratio|YCBD - Market Value to Book Value Ratio|Market Value to Book Value CYTO|Market Value to Book Value Ratio LIPO (Lipella Pharmaceuticals, Inc.)|Market Cap to Net Assets Ratio OptiNose Inc OPTN|Market Cap to Net Assets Ratio Pieris|Procaps Group Corp - Market Value to Book Value|PTPI - Market Value to Book Value Ratio|qlsyy.net (QLI) - Market Value to Book Value Ratio|SLRN - Market Cap to Net Assets Ratio|TFF Pharmaceuticals Inc. (TFFP) - Market Cap to Book Value Multiple